Mersana Therapeutics, Inc.
MRSN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $39 | $37 | $43 | $177 |
| - Cash | $56 | $77 | $102 | $108 |
| + Debt | $2 | $21 | $25 | $29 |
| Enterprise Value | -$15 | -$19 | -$35 | $98 |
| Revenue | $11 | $3 | $3 | $16 |
| % Growth | 260.2% | 11% | -83.2% | – |
| Gross Profit | $11 | $3 | $3 | $16 |
| % Margin | 100% | 90.6% | 100% | 100% |
| EBITDA | -$7 | -$23 | -$23 | -$13 |
| % Margin | -64.2% | -763.6% | -836.3% | -78.3% |
| Net Income | -$8 | -$24 | -$24 | -$14 |
| % Margin | -68.5% | -795% | -875.9% | -86.3% |
| EPS Diluted | -1.51 | -4.87 | -4.85 | -2.86 |
| % Growth | 69% | -0.4% | -69.6% | – |
| Operating Cash Flow | -$3 | -$23 | -$29 | -$19 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3 | -$23 | -$29 | -$19 |